Debiopharm Revenue and Competitors
Estimated Revenue & Valuation
- Debiopharm's estimated annual revenue is currently $98.8M per year.
- Debiopharm's estimated revenue per employee is $162,500
Employee Data
- Debiopharm has 608 Employees.
- Debiopharm grew their employee count by 5% last year.
Debiopharm's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Medicinal Chemistry | Reveal Email/Phone |
4 | Head Global Program Leadership & Project Management a.i. | Reveal Email/Phone |
5 | Head Strategic Partnering | Reveal Email/Phone |
6 | Head Clinical Development | Reveal Email/Phone |
7 | HEAD OF PEOPLE & CULTURE (HR), for BUSINESS DEVELOPMENT and R&D | Reveal Email/Phone |
8 | Head Early Commercial | Reveal Email/Phone |
9 | Head Clinical Trial Supply | Reveal Email/Phone |
10 | Director, Head Market Intelligence - General Secretary Strategic Committees | Reveal Email/Phone |
Debiopharm Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 26 | -4% | $15.7M | N/A |
#2 | $1.4M | 21 | -50% | $21.2M | N/A |
#3 | $41.9M | 293 | 8% | $6M | N/A |
#4 | $6M | 53 | -22% | $216.8M | N/A |
#5 | $0M | 2 | 0% | $33.3M | N/A |
#6 | $26M | 182 | 0% | N/A | N/A |
#7 | $30.9M | 221 | -26% | $64.6M | N/A |
#8 | $28.6M | 205 | -22% | $46.8M | N/A |
#9 | $249.1M | 1340 | 15% | $75M | N/A |
#10 | $12.4M | 95 | 3% | N/A | N/A |
What Is Debiopharm?
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe. Debiopharm International SA focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. Debiopharm completed the development and licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If you have interesting molecules and seek a competent and committed partner to develop them, please contact us.
keywords:N/AN/A
Total Funding
608
Number of Employees
$98.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Debiopharm News
AbbVie, Astellas Pharma, AstraZeneca, Debiopharm Group, Evotec AG, Kissei Pharmaceutical, Neurocrine Biosciences, ObsEva, Pfizer,...
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES. USA - English. USA -...
Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $630.9M | 2146 | 3% | N/A |
#2 | $1383.3M | 4066 | 5% | N/A |
#3 | $1471.5M | 7321 | 5% | N/A |
#4 | $5008.2M | 15690 | 12% | N/A |